News
Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the …
Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied …
The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primar…
PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which c…
Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal…
It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division.
At the 2017 American Acade…
There has been a significant amount of research and development in atopic dermatitis and psoriasis in the last couple of…
Marking 10 years of clinical experience using biosimilars, the European Medicines Agency (EMA) and the European Commissi…
Top 5 In Atopic Dermatitis